Compare ClearPoint Neuro Inc (CLPT) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Atlassian Corporation PLC — how do they compare? ClearPoint Neuro Inc trades at $14.45 (market cap $454.21M), while Atlassian Corporation PLC trades at $152.63 (market cap $39.10B). The key difference: Atlassian Corporation PLC is far larger — about 86.1× ClearPoint Neuro Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | TEAM | |
|---|---|---|
Market Cap | $454.21M | $39.10B |
Sector | Health | Technology |
52-Week High | $29.60 | $182.36 |
52-Week Low | $8.66 | $57.15 |
Enterprise Value | $488.79M | $39.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Atlassian (TEAM) stock trades at $151.87, up 1.88% today and near its 52-week high, reflecting strong momentum after a 35% surge post-Q4 earnings. The company reported 28% revenue growth to $1.77 billion, beating estimates, with cloud revenue accelerating to 31%. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals highlight robust growth amid negative net margins. Analyst sentiment is overwhelmingly positive, with 67% buy ratings and a $161.93 consensus target.
Outlook remains favorable driven by enterprise deal expansion and AI platform adoption, though risks include high valuation multiples (P/S 6.1, EV/EBITDA 184.26) and persistent net losses. Investors should weigh growth prospects against profitability challenges and market volatility. The stock's proximity to all-time highs suggests cautious optimism is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
